|
| Study ID | Year | Participants | Mean age (years) | Interventions | Treatment duration | Symptom improvement | Jadad score |
| Experimental | Control (prokinetic drugs) |
|
| Chen [13] | 2005 | 105 people
(38 men and 67 women) | 45.7 | XSLJZT (BID) | Domperidone
(10 mg, TID) | 4 weeks | (1) TER: 89.2% (58/65)
(2) TER: 72.5% (29/40) | 1 |
| Xiao [21] | 2005 | 77 people
(33 men and 44 women) | 43.0 | XSLJZT (BID) | Cisapride
(5 mg, TID) | 4 weeks | (1) TER: 74.4% (29/39)
(2) TER: 78.9% (30/38) | 1 |
| Gui [14] | 2003 | 80 people
(35 men and 45 women) | 46.1 | XSLJZT (BID) | Domperidone
(10 mg, TID) | 4 weeks | (1) TER: 87.5% (35/40)
(2) TER: 72.5% (29/40) | 2 |
| Li [15] | 2004 | 72 people
(27 men and 45 women) | 47.1 | XSLJZT (BID) | Domperidone
(10 mg, TID) | 4 weeks | (1) TER: 88.8% (32/36)
(2) TER: 72.2% (26/36) | 2 |
| Liang [25] | 2011 | 62 people
(28 men and 34 women) | 38.0 | XSLJZT (BID) | Mosapride
(5 mg, TID) | 4 weeks | (1) TER: 93.3% (28/30)
(2) TER: 78.1% (25/32) | 1 |
| Zhou [26] | 2010 | 60 people
(29 men and 31 women) | 35.9 | XSLJZT (BID) | Mosapride
(5 mg, TID) | 4 weeks | (1) TER: 90.0% (27/30)
(2) TER: 66.7% (20/30) | 2 |
| Li [22] | 2010 | 64 people
(35 men and 29 women) | 45.3 | XSLJZT (BID) | Cisapride
(5 mg, TID) | 4 weeks | (1) TER: 93.8% (30/32)
(2) TER: 78.1% (25/32) | 1 |
| Fan [16] | 2010 | 60 people
(29 men and 31 women) | 48.5 | XSLJZT (BID) | Domperidone
(10 mg, TID) | 4 weeks | (1) TER: 90.0% (27/30)
(2) TER: 70.0% (21/30) | 3 |
| Lu and Hong [17] | 2012 | 68 people
(40 men and 28 women) | 42.5 | XSLJZT (BID) | Domperidone
(10 mg, TID) | 4 weeks | (1) TER: 94.1% (32/34)
(2) TER: 85.3% (29/34) | 3 |
| Zhang and Shun [23] | 2002 | 64 people
(21 men and 43 women) | 44.3 | LJZT (BID) | Cisapride
(5 mg, TID) | 4 weeks | (1) TER: 93.9% (31/33)
(2) TER: 93.6% (29/31) | 2 |
| Tian and Wang [27] | 2005 | 160 people
(73 men and 87 women) | 34.4 | LJZT (BID) | Mosapride
(5 mg, TID) | 2 weeks | (1) TER: 85.0% (68/80)
(2) TER: 87.5% (70/80) | 2 |
| Chen and Zhang [18] | 2008 | 80 people
(37 men and 43 women) | 32.3 | LJZT (BID) | Domperidone
(10 mg, TID) | 4 weeks | (1) TER: 90.0% (36/40)
(2) TER: 75.0% (30/40) | 1 |
| Wang [19] | 2010 | 110 people
(56 men and 54 women) | 42.1 | LJZT (BID) | Domperidone
(10 mg, TID) | 4 weeks | (1) TER: 91.7% (55/60)
(2) TER: 74.0% (37/50) | 1 |
| Zhao and Che [24] | 2009 | 60 people
(46 men and 14 women) | 52.0 | LJZT (BID) | Cisapride
(5 mg, TID) | 4 weeks | (1) TER: 96.7% (29/30)
(2) TER: 80.0% (24/30) | 1 |
| Arai et al. [20] | 2012 | 27 people
(16 men and 11 women) | 57.8 | LJZT (TID) | Domperidone
(10 mg, TID) | 4 weeks | Not mentioned | 2 |
|
